Dr. Peter W. McLaughlin MD Medical Oncologist

Dr. Peter McLaughlin is a medical oncologist in Houston, Texas and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Tufts University School of Medicine and has been in practice for 40 years. He is one of 132 doctors at University of Texas M.D. Anderson Cancer Center who specialize in Medical Oncology.

Are you Dr. McLaughlin? Claim/Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology

Hospital Affiliation

University of Texas M.D. Anderson Cancer Center
Ranked #2 in Cancer

Education & Medical Training

Hartford Hospital
Residency, Internal Medicine, 1974–1977

University of Texas at Houston
Fellowship, Medical Oncology, 1978–1979

Tufts University School of Medicine
Class of 1974

Certifications & Licensure

American Board of Internal Medicine
Certified in Hematology

American Board of Internal Medicine
Certified in Internal Medicine

American Board of Internal Medicine
Certified in Medical Oncology

TX State Medical License
Active through 2015

Publications & Presentations

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
Oki, Y.,Westin, J. R.,Vega, F.,Chuang, H.,Fowler, N.,Neelapu, S.,Hagemeister, F. B.,McLaughlin, P.,Kwak, L. W.,Romaguera, J. E.,Fanale, M.,Younes, A.,Rodriguez, M. A.,Orlowski, R. Z.,Wang, M.,Ouzounian, S. T.,Samaniego, F.,Fayad, L.

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressi
Hagemeister, F.,Rodriguez, M. A.,Deitcher, S. R.,Younes, A.,Fayad, L.,Goy, A.,Dang, N. H.,Forman, A.,McLaughlin, P.,Medeiros, L. J.,Pro, B.,Romaguera, J.,Samaniego, F.,Silverman, J. A.,Sarris, A.,Cabanillas, F.

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Oki, Y.,Younes, A.,Copeland, A.,Hagemeister, F.,Fayad, L. E.,McLaughlin, P.,Shah, J.,Fowler, N.,Romaguera, J.,Kwak, L. W.,Pro, B.

See all 76 publications

Report a Correction — If you are aware of information on this page that is out of date or incorrect, please let us know.

Patient Advice & Support

See More
Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Nearby Medical Oncologists

See all Medical Oncologists near Houston, TX See all Medical Oncologists in Texas

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.